Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Colorectal Cancer

TheraSphere® Metastatic Colorectal Carcinoma of the Liver (7627 - TS-102)
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Status Conditions Phase Study ID
Recruiting Colorectal Cancer Phase III 7627
NCT01483027
Summary

The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.


Investigator
William Harris
Location    
Seattle Cancer Care Alliance 800-804-8824  
Olympic Medical Center, Sequim WA 360-683-9895  
Skagit Valley Hospital, Mt. Vernon WA 360-424-2687  
Group Health 206-225-7893  
SCCA at EvergreenHealth 425-899-3337  
Eligibility Criteria (must meet the following to participate in this study)

Inclusion Criteria:

  • Colorectal cancer with metastases progressed after first line treatment

Exclusion Criteria:

  • Contraindications to TheraSphere or second line chemotherapy
Exclusions (conditions that would prevent participation in this study)

Last Updated
September 24, 2013
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.